Loading clinical trials...
Loading clinical trials...
A Phase 2, Subprotocol of DAY101 Monotherapy for Patients With Recurrent, Progressive, or Refractory Solid Tumors With MAPK Pathway Aberrations
Conditions
Interventions
Tovorafenib
Locations
20
United States
The Angeles Clinic
Los Angeles, California, United States
Hoag Health
Newport Beach, California, United States
University of Colorado Hospital
Aurora, Colorado, United States
Cancer Specialists of North Florida
Jacksonville, Florida, United States
Community North Cancer Center
Indianapolis, Indiana, United States
OHSU Knight Cancer Institute
Portland, Oregon, United States
Start Date
July 15, 2021
Primary Completion Date
July 8, 2024
Completion Date
July 8, 2024
Last Updated
October 2, 2025
NCT06132828
NCT04570423
NCT06144671
NCT07489378
NCT06926283
NCT07177937
Lead Sponsor
Day One Biopharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions